HALL heads into the final week of April having shed 10% in a single session, trading at $0.07 on the OTC Pink market — a price that tells the real story about where this name now sits.
The week's most notable tension is a stock trading well below a cent above zero, with almost no market infrastructure around it. Price data is stale by seven days, no next earnings event is on record, and the options history last registered in December 2022. The data that does arrive paints a picture of a company in deep distress, not one in active short-seller crosshairs.
The positioning picture is, paradoxically, quiet. Short interest has held flat at 1,461 shares for at least the past six weeks — the number has not moved a single share over the entire history of the estimate window. That frozen reading signals not short conviction but near-complete illiquidity; there is simply no active borrow market to speak of. Availability is running at roughly 96% of the lending pool still unused, well below the 52-week peak of 8.6% utilisation, meaning the few shares that could theoretically be borrowed are almost entirely untouched. The cost-to-borrow data is flagged stale, last recorded in October 2025 at 16.5% — elevated for a name of this size, though the figure has eased from a range closer to 22% that persisted through most of 2024. The ORTEX short score, at 35.8, has drifted gently lower from a brief spike to 42.4 on April 23 — a one-day anomaly that faded within 24 hours and left no lasting imprint on positioning.
The Street has effectively gone silent on this name. No analyst data is current. The only valuation figure on file is an enterprise value estimate of approximately $61 million from March 2025, now over a year old. Factor scores flag a dividend rank of just 15 and a days-to-cover rank of 18 — both consistent with a name where liquidity and income have all but disappeared. The sector score lands at 50, exactly mid-table, which in this context means the model has little to differentiate it from the broader property and casualty insurance cohort.
Insider data tells a similarly dormant story. The most recent recorded trade is a director purchase of 30,000 shares in January 2022, at $4.64 — a price nearly 66 times the current level. That transaction, worth $139,200, now represents a loss of more than 98%. No insider activity has been recorded since. The earlier history of the register shows a mix of small executive buys in 2018 and 2019 and modest director sales, none of which are relevant to the current setup.
Earnings reactions offer the only live data point worth noting. The August 2025 print triggered a 6.5% single-day decline. The April 2025 event saw a 9.4% one-day gain that was almost entirely reversed over the following five sessions, netting to a -0.6% five-day move. The pattern is of sharp but short-lived reactions in an illiquid name, where a handful of trades can move the price materially in either direction without reflecting genuine institutional conviction.
With no confirmed next earnings date, stale price data, and a short interest figure that has not moved in months, the next meaningful signal for HALL is likely to come from any regulatory filing or corporate announcement that breaks the current information vacuum rather than from positioning shifts in the lending market.
See the live data behind this article on ORTEX.
Open HALL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
